197 related articles for article (PubMed ID: 34191975)
1. Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework.
Degtyarev E; Rufibach K; Shentu Y; Yung G; Casey M; Englert S; Liu F; Liu Y; Sailer O; Siegel J; Sun S; Tang R; Zhou J;
Stat Biopharm Res; 2020 Jul; 12(4):427-437. PubMed ID: 34191975
[No Abstract] [Full Text] [Related]
2. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
Lawrance R; Degtyarev E; Griffiths P; Trask P; Lau H; D'Alessio D; Griebsch I; Wallenstein G; Cocks K; Rufibach K
J Patient Rep Outcomes; 2020 Aug; 4(1):68. PubMed ID: 32833083
[TBL] [Abstract][Full Text] [Related]
3. Application of estimand framework in ICH E9 (R1) to safety evaluation.
Wang X; Yang P; Yuan SS; Wang WWB
J Biopharm Stat; 2023 Jul; 33(4):476-487. PubMed ID: 36951445
[TBL] [Abstract][Full Text] [Related]
4. Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.
Degtyarev E; Zhang Y; Sen K; Lebwohl D; Akacha M; Hampson LV; Bornkamp B; Maniero A; Bretz F; Zuber E
JCO Precis Oncol; 2019 Dec; 3():1-10. PubMed ID: 35100723
[TBL] [Abstract][Full Text] [Related]
5. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
[TBL] [Abstract][Full Text] [Related]
6. Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development.
Englert S; Mercier F; Pilling EA; Homer V; Habermehl C; Zimmermann S; Kan-Dobrosky N
Pharm Stat; 2023; 22(5):921-937. PubMed ID: 37403434
[TBL] [Abstract][Full Text] [Related]
7. Estimands in hematologic oncology trials.
Sun S; Weber HJ; Butler E; Rufibach K; Roychoudhury S
Pharm Stat; 2021 Jul; 20(4):793-805. PubMed ID: 33686762
[TBL] [Abstract][Full Text] [Related]
8. Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.
Qu Y; Lipkovich I
Ther Innov Regul Sci; 2021 Sep; 55(5):984-988. PubMed ID: 33983621
[TBL] [Abstract][Full Text] [Related]
9. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework.
Grobler AC; Lee KJ; Wong A; Currow DC; Braat S
J Pain Symptom Manage; 2022 Apr; 63(4):e431-e439. PubMed ID: 34954068
[TBL] [Abstract][Full Text] [Related]
10. Application of the Estimand Framework to Anesthesia Trials.
De Silva AP; Leslie K; Braat S; Grobler AC
Anesthesiology; 2024 Jul; 141(1):13-23. PubMed ID: 38743905
[TBL] [Abstract][Full Text] [Related]
11. Incorporating estimands into clinical trial statistical analysis plans.
Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
[TBL] [Abstract][Full Text] [Related]
12. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
Jin M; Liu G
Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
[TBL] [Abstract][Full Text] [Related]
13. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.
Rehal S; Cro S; Phillips PP; Fielding K; Carpenter JR
Clin Trials; 2023 Oct; 20(5):497-506. PubMed ID: 37277978
[TBL] [Abstract][Full Text] [Related]
14. Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
Casey M; Degtyarev E; Lechuga MJ; Aimone P; Ravaud A; Motzer RJ; Liu F; Stalbovskaya V; Tang R; Butler E; Sailer O; Halabi S; George D
Pharm Stat; 2021 Mar; 20(2):324-334. PubMed ID: 33155417
[TBL] [Abstract][Full Text] [Related]
15. Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
[TBL] [Abstract][Full Text] [Related]
16. Estimands-A Basic Element for Clinical Trials.
Pohl M; Baumann L; Behnisch R; Kirchner M; Krisam J; Sander A
Dtsch Arztebl Int; 2021 Dec; 118(51-52):883-888. PubMed ID: 34857075
[TBL] [Abstract][Full Text] [Related]
17. Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond.
Rufibach K
Pharm Stat; 2019 Mar; 18(2):145-165. PubMed ID: 30478869
[TBL] [Abstract][Full Text] [Related]
18. Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidance.
Siegel JM; Weber HJ; Englert S; Liu F; Casey M;
Pharm Stat; 2024 Mar; ():. PubMed ID: 38553421
[TBL] [Abstract][Full Text] [Related]
19. Use of the Estimand Framework to Manage the Disruptive Effects of COVID-19 on Stroke Clinical Trials.
Yassi N; Hayward KS; Campbell BCV; Churilov L
Stroke; 2021 Nov; 52(11):3739-3747. PubMed ID: 34587797
[TBL] [Abstract][Full Text] [Related]
20. Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
Qu Y; Shurzinske L; Sethuraman S
Pharm Stat; 2021 Mar; 20(2):314-323. PubMed ID: 33098267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
